(Q45223569)

11 December 2017

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial (English)

1 reference

11 December 2017

Toshio Ogihara

1

1 reference

11 December 2017

Akira Fujimoto

2

1 reference

11 December 2017

Kazuwa Nakao

3

1 reference

11 December 2017

Takao Saruta

4

1 reference

11 December 2017

CASE-J Trial Group

5

1 reference

11 December 2017

1 October 2008

1 reference

Expert Review of Cardiovascular Therapy

11 December 2017

1 reference

11 December 2017

6

1 reference

11 December 2017

9

1 reference

11 December 2017

1195-1201

1 reference

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

11 December 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Angiotensin receptors and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Prognostic significance of left ventricular mass change during treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Adverse prognostic significance of new diabetes in treated hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.9.1195

10.1586/14779072.6.9.1195

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference